Free Trial
NASDAQ:KRRO

Korro Bio Q2 2024 Earnings Report

Korro Bio logo
$15.22 +1.30 (+9.30%)
Closing price 03:59 PM Eastern
Extended Trading
$15.40 +0.18 (+1.15%)
As of 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Korro Bio EPS Results

Actual EPS
-$2.43
Consensus EPS
-$2.39
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Korro Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Korro Bio Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

Korro Bio's Q2 2025 earnings is scheduled for Tuesday, May 13, 2025

Korro Bio Earnings Headlines

Korro Bio to Cut 20% of Workforce
Korro Bio to Cut 20% of Workforce
It may already be too late…
A global energy shift is underway—and lithium is at the center of it. From electric vehicles to grid storage and consumer tech, demand for lithium is surging with no signs of slowing down. But here’s the problem: supply is struggling to keep up.
Cantor Fitzgerald Weighs in on Korro Bio FY2025 Earnings
See More Korro Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Korro Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Korro Bio and other key companies, straight to your email.

About Korro Bio

Korro Bio (NASDAQ:KRRO), a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

View Korro Bio Profile

More Earnings Resources from MarketBeat